Topic analysis

COVID pioneer BioNTech: The fall of Germany's pandemic hero

BioNTech, the German biotech firm that co-developed the first approved mRNA COVID-19 vaccine Comirnaty with Pfizer, is facing significant challenges including plummeting vaccine demand, a €532 million quarterly loss, and restructuring measures—such as closing production sites in Germany and Singapore (affecting ~1,860 jobs), shifting all COVID vaccine manufacturing to Pfizer, and the upcoming end-of-year departure of founders Ugur Sahin and Özlem Türeci. The company is pivoting its focus to late-stage mRNA cancer treatments, aiming to launch 15 Phase 3 trials by the end of 2026, in an effort to avoid being seen as a one-hit wonder while targeting €500 million in annual cost savings by 2029.